Advanced search
Publication Cover
Future Oncology Volume 14, 2018 - Issue 14
Submit an article Journal homepage
529
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Negative Prognostic Factors and Resulting Clinical Outcome in Patients with Metastatic Renal Cell Carcinoma Included in the Italian Nivolumab-Expanded Access Program

Sergio Bracarda1 Azienda USL Toscana SudEst, Arezzo, ItalyCorrespondence[email protected]
,
Luca Galli2 AOU Pisana ‘Spedali Riuniti di S Chiara’, Pisa, Italy
,
Marco Maruzzo3 Istituto Oncologico Veneto, IOV IRCCS, Padova, Italy
,
Giovanni Lo Re4 Oncologia Pordenone-S Vito, CRO Aviano, Pordenone, Italy
,
Sebastiano Buti5 Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
,
Adolfo Favaretto6 AULSS 2 Marca Trevigiana, Treviso, Italy
,
Francesco Di Costanzo7 AOU Careggi, Firenze, Italy
,
Cosimo Sacco8 AOU ‘Santa Maria della Misericordia’, Udine, Italy
,
Marco Merlano9 AO ‘S Croce e Carle’, Cuneo, Italy
,
Claudia Mucciarini10 Ospedale di Carpi, Carpi, Italy
,
Elena Zafarana11 AUSL4 – Nuovo Ospedale di Prato, Prato, Italy
,
Sante Romito12 Ospedali Riuniti di Foggia, Foggia, Italy
,
Antonio Maestri13 Ospedale ‘S Maria della Scaletta’, Imola, Italy
,
Carmelo G Giorgio14 Ospedale ‘Gravina e Santo Pietro’, Caltagirone, Italy
,
Maria T Ionta15 AOU di Cagliari, Cagliari, Italy
,
Daniele Turci16 Presidio Ospedaliero ‘S Maria delle Croci’, Ravenna, Italy
,
Ugo De Giorgi17 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
,
Giuseppe Procopio18 Istituto Nazionale dei Tumori, Milano, Italy
,
Enrico Cortesi19 Policlinico Umberto I, Roma, Italy
,
Diana Giannarelli20 IRCCS Istituto Regina Elena, Roma, Italy
&
Camillo Porta21 IRCCS Policlinico ‘S Matteo’, Pavia, Italy
 show all
Pages 1347-1354 | Received 25 Oct 2017, Accepted 29 Jan 2018, Published online: 18 May 2018

References

  • Calvo E , SchmidingerM, HengDYet al. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer Treat. Rev.50, 109–117 (2016).
  • Gore ME , HariharanS, PortaCet al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer117(3), 501–509 (2011).
  • Vickers MM , Al-HarbiH, ChoueiriTKet al. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. Clin. Genitourin. Cancer11(3), 311–315 (2013).
  • Seidel C , FennerM, ReuterCet al. Retrospective analyses of patient characteristics having predictive impact on survival under everolimus. Onkologie34(3), 111–114 (2011).
  • McKay RR , KroegerN, XieWet al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur. Urol.65(3), 577–584 (2014).
  • Golshayan AR , GeorgeS, HengDYet al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J. Clin. Oncol.27(2), 235–241 (2009).
  • Tannir NM , JonaschE, AlbigesLet al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter Phase II trial. Eur. Urol.69(5), 866–874 (2016).
  • Unverzagt S , MoldenhauerI, NothackerMet al. Immunotherapy for metastatic renal cell carcinoma. Cochrane Database Syst. Rev.5, CD011673 (2017).
  • Gill D , HahnAW, SonpavdeG, AgarwalN. Immunotherapy of advanced renal cell carcinoma: current and future therapies. Hum. Vaccin. Immunother.12(12), 2997–3004 (2016).
  • Cho YH , KimMS, ChungHS, HwangEC. Novel immunotherapy in metastatic renal cell carcinoma. Investig. Clin. Urol.58(4), 220–227 (2017).
  • Motzer RJ , EscudierB, McDermottDFet al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med.373(19), 1803–1813 (2015).
  • Rizzo M , CartenìG, PappagalloG. We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC. Future Oncol.10(12), 1893–1896 (2014).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.